Blueprint Medicines Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Blueprint Medicines (BPMC) Misses Q2 EPS by 13c, Revenues Beat
August 1, 2019 7:23 AM EDTBlueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($2.04), $0.13 worse than the analyst estimate of ($1.91). Revenue for the quarter came in at $5.11 million versus the consensus estimate of $1.98 million.
Second Quarter 2019 Financial Results:
Cash Position: As of June 30, 2019, cash, cash equivalents and investments were $667.3 million, as compared to $494.0 million as of December 31, 2018. This increase reflects net proceeds of approximately $327.4 million from the company's follow-on underwritten public offering of common stock, which closed in April 2019, partially offset by cash used in operations.Collaboration Revenues: Collaboration revenues were $5.1 million for the second quarter... More